ArticlePlastic and reconstructive surgery. Global open2026
Analysis of Essence Human Acellular Dermal Matrix Compared With Other Products in Prepectoral Direct-to-implant Reconstruction.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acellular dermal matrices (ADMs) are widely used in implant-based breast reconstruction, with outcomes potentially varying across human-derived products. With the availability of newer ADMs, this study compares outcomes among different ADMs used in direct-to-implant (DTI) reconstruction. Methods: We prospectively reviewed patients undergoing immediate prepectoral DTI at a single institution (February 2020-September 2025). We compared early postoperative outcomes (within 90 d) among 3 human ADM products (Essence, AlloDerm, and Cortiva). Analyses were performed per patient. Cohorts were compared using univariate tests; multivariable logistic regression adjusted for age, body mass index, smoking, diabetes, radiation exposure, chemotherapy exposure, mastectomy type, and total resection weight. Results: A total of 487 patients were included (Essence, n = 68; AlloDerm, n = 201; Cortiva, n = 218), with similar mean age across groups (~52-54 y). Mean implant size differed across cohorts ( Conclusions: Essence ADM demonstrates comparable safety and outcomes compared with other human ADMs for immediate prepectoral DTI reconstruction despite its use in higher risk patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.